Denali Therapeutics Inc. Overview
Pro stress-test →Denali Therapeutics is a biopharmaceutical company that discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company is focused on its portfolio of investigational therapies for neurodegenerative diseases, lysosomal storage disorders and other serious diseases. 2026 is a defining year for Denali as it prepares to deliver its first TV-enabled medicine to patients.
Strategic Profile
Pro stress-test →Denali is on the cusp of launching tividenofusp alfa, which the company believes will establish a new standard of care for people living with Hunter syndrome and mark the first commercial validation of its platform. The company expects multiple clinical data readouts across its portfolio and plans to advance two TV-enabled programs into clinical studies for Alzheimer's disease and a program for Pompe disease. The company leverages its proprietary TransportVehicle (TV) platform to enable delivery of biotherapeutics across the blood-brain barrier and throughout the body.
Competitive Landscape
Pro stress-test →Denali competes in rare disease and neurodegenerative disease markets with programs including eclitasertib (RIPK1 inhibitor), LRRK2 inhibitors (BIIB122), DNL343 (eIF2B activator for ALS), and multiple enzyme replacement therapies and TransportVehicle programs for conditions like MPS II, MPS IIIA, Pompe disease, and Alzheimer's disease. Primary competitors include other biotech firms focused on lysosomal storage disorders and neurodegeneration.
Industry Context
Denali Therapeutics Inc. operates in Biopharmaceutical - Rare Diseases & Neurodegenerative Therapeutics.
Key facts
Headquarters: South San Francisco, US · Revenue: $0